

Features:

- Contains all-new chapters on COVID-19, vaccine hesitancy, and non-specific effects of vaccines, as well as significantly revised content on new vaccine technologies such as mRNA vaccines, emerging vaccines, and technologies to improve immunization.
- Presents exciting new data on evolution of adjuvants across the centuries, dengue vaccines, human papillomavirus vaccines, respiratory syncytial virus vaccines, tuberculosis vaccines, and zoster vaccines.
- Provides up-to-date, authoritative information on vaccine production, available preparations, efficacy and safety, and recommendations for vaccine use, with rationales and data on the impact of vaccination programs on morbidity and mortality.
- Provides complete coverage of each disease, including clinical characteristics, microbiology, pathogenesis, diagnosis, and treatment, as well as epidemiology and public health and regulatory issues.
- Keeps you up to date with information on each vaccine, including its stability, immunogenicity, efficacy, duration of immunity, adverse events, indications, contraindications, precautions, administration with other vaccines, and disease-control strategies.
- Covers vaccine-preventable diseases, vaccine science, and licensed vaccine products, as well as product technologies and global regulatory and public health issues.
- Analyzes the cost-benefit and cost-effectiveness of different vaccine options.
- Helps you clearly visualize concepts and objective data through an abundance of tables and figures.
- Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices.

Περιεχόμενα:**SECTION I****General Aspects of Vaccination**

- 1 A Short History of Vaccination
- 2 Vaccine Immunology
- 3 Non-specific Effects of Vaccines
- 4 Correlates of Protection
- 5 The Vaccine Industry
- 6 Vaccine Manufacturing
- 7 Evolution of Adjuvants Across the Centuries
- 8 Vaccine Additives and Manufacturing Residuals in Vaccines Licensed in the United States
- 9 Passive Immunization

SECTION II**Licensed Vaccines and Vaccines in Development**

- 10 General Immunization Practices
- 11 Human Adenovirus Vaccines
- 12 Anthrax Vaccines
- 13 Biodefense Vaccines, Vaccines for Emerging Infectious Diseases, and Coalition for Epidemic Preparedness Innovations (CEPI)
- 14 Cancer Vaccines
- 15 Cholera Vaccines
- 16 Combination Vaccines
- 17 Coronavirus Vaccines
- 18 Cytomegalovirus Vaccines
- 19 Dengue Vaccines
- 20 Vaccines Against Diarrhea Caused by Noncholera Bacteria
- 21 Diphtheria Toxoid

- 22 Ebola Vaccines
- 23 Nonpolio Enteroviruses
- 24 Epstein–Barr Virus Vaccines
- 25 Haemophilus Influenzae Type b Vaccines
- 26 Hepatitis A Vaccines
- 27 Hepatitis B Vaccines
- 28 Hepatitis C Vaccines
- 29 Hepatitis E Vaccines
- 30 Herpes Simplex Virus Vaccines
- 31 Human Immunodeficiency Virus Vaccines
- 32 Human Papillomavirus Vaccines
- 33 Inactivated and Recombinant Influenza Vaccines
- 34 Influenza Vaccine—Live
- 35 Japanese Encephalitis Vaccines
- 36 Lyme Disease Vaccines—the Journey Continues
- 37 Malaria Vaccines
- 38 Measles Vaccines
- 39 Meningococcal Capsular Group A, C, W, and Y Conjugate Vaccines
- 40 Meningococcal Vaccines Directed at Capsular Group B
- 41 Mumps Vaccines
- 42 Noninfectious Disease Vaccines
- 43 Norovirus
- 44 Parasitic Disease Vaccines
- 45 Pertussis Vaccines
- 46 Plague Vaccines
- 47 Pneumococcal Conjugate Vaccine and Pneumococcal Common Protein Vaccines
- 48 Pneumococcal Polysaccharide Vaccines
- 49 Poliovirus Vaccine—Inactivated
- 50 Poliovirus Vaccine—Live
- 51 Lyssaviruses and Rabies Vaccines
- 52 Respiratory Syncytial Virus Vaccines and Monoclonal Antibodies
- 53 Rotavirus Vaccines
- 54 Rubella Vaccines
- 55 Smallpox and Vaccinia
- 56 Staphylococcus aureus Vaccines
- 57 Streptococcus Group A Vaccines
- 58 Streptococcus Group B Vaccines
- 59 Tetanus Toxoid
- 60 Tickborne Encephalitis Vaccines
- 61 Tuberculosis Vaccines
- 62 Typhoid Fever Vaccines
- 63 Varicella Vaccines
- 64 Yellow Fever Vaccine
- 65 Zika Virus Vaccines
- 66 Zoster Vaccines

SECTION III

New Technologies

- 67 Technologies for Making New Vaccines
- 68 Genetic-Based Vaccine Vectors
- 69 Technologies to Improve Immunization

SECTION IV

Vaccination of Special Groups

- 70 Vaccination of Immunocompromised Hosts
- 71 Vaccines for International Travel
- 72 Vaccines for Healthcare Personnel
- 73 Vaccination of Pregnant Women

SECTION V

Public Health and Regulatory Issues

- 74 Immunization in the United States
- 75 Immunization in Europe
- 76 Immunization and Vaccine-Preventable Diseases in the Asia-Pacific Region
- 77 Immunization in Low- and Middle-Income Countries
- 78 Community Protection
- 79 Economic Analyses of Vaccine Policies
- 80 Regulation and Testing of Vaccines in the US
- 81 Regulation of Vaccines in Europe
- 82 Regulation of Vaccines in Low- and Middle-Income Countries
- 83 Vaccine Safety
- 84 Vaccine Hesitancy and Behavioral Factors Associated With Vaccine Uptake
- 85 Legal Issues
- 86 Ethics

ONLINE ONLY

- 87 Vaccines to Prevent Mpox

APPENDIX

- Websites and Applications for Mobile Devices With Information About Immunization

Index